ALPL

Across TCGA pan-cancer cohorts, ALPL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALPL data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALPL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALPL expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, KICH, and STAD are the cancer types where ALPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.768	<.001	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	All	0.222	0.729	.004	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	II,III,IV	1.000	0.830	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALPL–LUAD (DFS)

Open the LUAD breakdown →